Half-Time Outlook 2026-27: AI holds the score...

About a year ago Europe announced some ambitious commitments for rearmament. Has it actually delivered? The story is complicated, as our AI Assistants Aria and Bob explain in this new episode of Tomorrow. Read the full report here: European defense one year on: Money is not the p ...  Show more

This week on the Tomorrow podcast, we dive into the Allianz Global Wealth Report 2026. The big picture: Global financial assets jumped to a record EUR268.4trn in 2025, up +8.6% from the previous year. But it’s not because households are not saving more – markets accounted for 4 o ...  Show more

First they treated diabetes. Then obesity. Now <a href="https://www.economist.com/leaders/2024/10/24/its-not-just-obesity-drugs-like-ozempic-will-change-the-world?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.t ...

How much harm has been done by decades of governments investing too little? Is buy-now-pay-later causing misery or joy for young shoppers? Are supermarkets cutting prices fast enough? Is Novo Nordisk’s anti obesity wonder drug Semaglutide the most important pharmaceutical discove ...  Show more

 Bloomberg News Health Reporter Madison Muller explains how Pfizer’s second weight-loss setback this year is a warning sign that breaking into the lucrative obesity market isn’t going to be easy. Cory Klippsten, CEO at Swan Bitcoin, shares his crypto outlook for 2024. Benjamin Wo ...  Show more